ClinicalTrials.gg

Asthma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 4,848 studies for Asthma across more than 10 countries. 605 are recruiting or about to start. 4,239 of them are mainly about Asthma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 2 narrower conditions too, such as Asthma, Exercise-Induced: 4,897 studies, 607 open.

ClinicalTrials.gov finds 5,318 studies for Asthma. How that becomes 4,846 here

This page counts the studies the registry files under Asthma, and those it files under no condition that list Asthmathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 5,318Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −49Filed under a narrower condition, counted on its own pageAsthma, Exercise-Induced 32 · Status Asthmaticus 17
  3. −250List Asthma as a condition, but the registry did not file them under itMost often written as “Asthma in Children” (53), “Allergic Asthma” (33), and “Severe Eosinophilic Asthma” (15). The registry filed them under other conditions only, most often Pulmonary Eosinophilia (40) and Rhinitis, Allergic (37).
  4. −173Match it another way112 name it in the title, 21 in a keyword, and 40 by a synonym or other text the search reads.
  5. 4,846The count on this page372 of them list Asthma in their own words; the registry filed them under no condition.

Status

Completed
3,299
Recruiting
417
Status unknown
392
Terminated
255
Not yet recruiting
161
Withdrawn
159

Phase

Phase 2
716
Phase 3
640
Phase 4
458
Phase 1
418
Early Phase 1
27

Where

United States
1,695
United Kingdom
558
Canada
428
Germany
385
France
296
Poland
255

Who develops what

Add Asthma to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 73 programs from 46 companies, 71 with this as their studies’ main aim; 17 with a live phase 3 study; 17 primary completions in the next 12 months. Compare AstraZeneca, Chiesi Farmaceutici and GlaxoSmithKline here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
AlbuterolRecent, repeated
Evidence
  • NCT07807007 · Chenpon Pharmaceutical · Phase 2 · background · “Albuterol Sulfate” · registered Aug 2026
  • NCT06676319 · Sanofi · Phase 2 · live · background · “Budesonide/Albuterol” · registered Nov 2024
  • NCT06664619 · Teva Pharmaceutical Industries, Ltd. · Phase 3 · comparator · “ABS” · registered Oct 2024
  • NCT06563102 · AstraZeneca · Phase 4 · comparator · “Albuterol” · registered Aug 2024
  • NCT06473779 · AstraZeneca · Phase 3 · live · background · “Albuterol/budesonide (AIRSUPRA®)” · registered Jun 2024
GlaxoSmithKline21% of its industry studiesUS: off-patent, 27 generics marketed57 studies
FluticasoneRecent, repeated
Evidence
  • NCT06676319 · Sanofi · Phase 2 · live · background · “Fluticasone/Salmeterol” · registered Nov 2024
  • NCT06664619 · Teva Pharmaceutical Industries, Ltd. · Phase 3 · comparator · “FP” · registered Oct 2024
  • NCT06572228 · Regeneron Pharmaceuticals · Phase 4 · live · background · “ICS/LABA” · registered Aug 2024
  • NCT05776927 · Novartis · Phase 3 · live · background · “Salmeterol Xinafoate / Fluticasone Propionate” · registered Mar 2023
  • NCT05363202 · glenmark pharmaceuticals ltd india · Phase 3 · comparator · “FLOVENT HFA 44 mcg” · registered May 2022
GlaxoSmithKline35% of its industry studiesUS: off-patent, 25 generics marketed55 studies
BudesonideRecent, repeated
Evidence
  • NCT07807007 · Chenpon Pharmaceutical · Phase 2 · comparator · “Budesonide and Formoterol Fumarate” · registered Aug 2026
  • NCT06676319 · Sanofi · Phase 2 · live · background · “Budesonide/Formoterol” · registered Nov 2024
  • NCT05562466 · Novartis · Phase 3 · live · comparator · “Budesonide” · registered Sep 2022
  • NCT02573233 · Sanofi · Phase 2 · background · “budesonide and formoterol” · registered Oct 2015
  • NCT02446418 · GlaxoSmithKline · Phase 3 · comparator · “Budesonide” · registered May 2015
AstraZeneca41% of its industry studiesUS: off-patent, 16 generics marketedEU: Dr. Falk Pharma GmbH (EMA 2018) + 1 other33 studies
formoterolRecent, repeated
Evidence
  • NCT07807007 · Chenpon Pharmaceutical · Phase 2 · comparator · “Budesonide and Formoterol Fumarate” · registered Aug 2026
  • NCT07318350 · Eurofarma Laboratorios S.A. · Phase 3 · comparator · “Alenia® (Formoterol 6 mcg / Budesonide 200 mcg)” · registered Dec 2025
  • NCT06676319 · Sanofi · Phase 2 · live · background · “Budesonide/Formoterol” · registered Nov 2024
  • NCT02573233 · Sanofi · Phase 2 · background · “budesonide and formoterol” · registered Oct 2015
  • NCT02446418 · GlaxoSmithKline · Phase 3 · comparator · “Formoterol Fumarate” · registered May 2015
AstraZeneca42% of its industry studiesUS: off-patent, 11 generics marketed33 studies
OmalizumabRecent, repeated
Evidence
  • NCT07342803 · Longbio Pharma · Phase 2 · live · comparator · “Omalizumab” · registered Dec 2025
  • NCT06438757 · Jemincare · Phase 2 · comparator · “Omalizumab” · registered May 2024
  • NCT05813470 · cinnagen · Phase 3 · comparator · “Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)” · registered Apr 2023
  • NCT04607629 · AO GENERIUM · Phase 3 · comparator · “Xolair® + Symbicort®” · registered Oct 2020
Novartis49% of its industry studiesUS: Hoffmann-La Roche (FDA 2003) + 1 otherEU: Novartis (EMA 2005) + 1 other33 studies
Salmeterol XinafoateRecent, repeated
Evidence
  • NCT06676319 · Sanofi · Phase 2 · live · background · “Fluticasone/Salmeterol” · registered Nov 2024
  • NCT05776927 · Novartis · Phase 3 · live · background · “Salmeterol Xinafoate / Fluticasone Propionate” · registered Mar 2023
  • NCT03387241 · Mundipharma · Phase 3 · comparator · “fluticasone/ salmeterol” · registered Nov 2017
  • NCT03158311 · Novartis · Phase 3 · comparator · “Salmeterol/fluticasone plus tiotropium” · registered May 2017
  • NCT02573233 · Sanofi · Phase 2 · background · “fluticasone propionate and salmeterol” · registered Oct 2015
GlaxoSmithKline51% of its industry studiesUS: off-patent, 5 generics marketed22 studies

14 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
benralizumabApproved: US 2017 · EU 2018☆ Track2 live phase-3 studies: NCT05692180, NCT07444567AstraZeneca
HFA-152a☆ Track1 live phase-3 study: NCT07645248GlaxoSmithKline
norflurane☆ Track1 live phase-3 study: NCT07645248GlaxoSmithKline
depemokimabApproved: US 2025 · EU 2026☆ Track3 live phase-3 studies: NCT07671001, NCT07456033, NCT06979323GlaxoSmithKline
tezepelumabApproved: US 2021 · EU 2022☆ Track3 live phase-3 studies: NCT06023589, NCT07363642, NCT06473779AstraZeneca

The 5 in phase 3 with the nearest primary completion, of 73 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (17)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.rademikibart · Connect Biopharm LLC · Phase 2 main aimNCT07705737 Rademikibart IV for Acute Asthma and COPD Exacerbation — primary endpoint: Change from baseline in post-BD FEV1 · 40 enrolled
  • Dec 2026 est.ENV-294 · Enveda Therapeutics · Phase 2 main aimNCT07301255 ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults — primary endpoint: Incidence and Severity of Adverse Events · 50 enrolled
  • 23 Dec 2026 est.benralizumab · AstraZeneca · Phase 3 main aimNCT05692180 A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma — primary endpoint: Time to first asthma exacerbation · 94 enrolled

14 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Asthma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Corticosteroids 10 open · Bronchodilators 8 open · Antimuscarinics 3 open · Tyrosine kinase inhibitors (TKIs) 1 open · JAK inhibitors 1 open

Coming up

213studies finish main data collection within a year16 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger. 147 (35%) take children under 18. 4 (1%) are for women only and 0 (0%) for men only; 105 (25%) take healthy volunteers.

Recruiting studies that take each age, of 417
AgeWomenMen
10101 (24%)101 (24%)
18325 (78%)322 (77%)
30330 (79%)326 (78%)
40331 (79%)328 (79%)
50319 (76%)319 (76%)
65300 (72%)300 (72%)
75255 (61%)255 (61%)
85187 (45%)187 (45%)

Across all 4,848 studies, recruiting or not: 61% stop at 75 or younger and 50% at 65; 42% take children; 1% are for women only and 2% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Asthma studies take

Of 205 phase 3 interventional studies under Asthma, half reached primary completion within 27 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 16 mo3–14 · 200 studies6 mo3–12 · 173 studies—
Phase 220 mo12–41 · 199 studies16 mo10–23 · 137 studies46 mo28–62 · 62 studies
Phase 2/328 mo12–59 · 14 studies——
Phase 327 mo14–42 · 205 studies25 mo14–41 · 173 studies35 mo18–54 · 32 studies
Phase 424 mo11–37 · 156 studies21 mo9–33 · 66 studies27 mo12–51 · 90 studies
Interventional, no phase23 mo10–48 · 649 studies12 mo5–24 · 50 studies24 mo11–50 · 599 studies
Observational36 mo18–82 · 455 studies27 mo17–58 · 90 studies38 mo18–99 · 365 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered18

Show 13 more

Studies

Recruiting first, then most recently updated. Showing 50 of 4,848. Browse all 4,848 → or search them.